Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Relx reports year of solid growth for revenue, earnings

(Sharecast News) - Relx reported a "strong" set of financial results for 2024 on Thursday, reporting revenue of £9.43bn, up 7% on an underlying basis. The FTSE 100 information and events specialist said adjusted operating profit rose 10% to £3.2bn, with its adjusted operating margin improving to 33.9% from 33.1%, driven by process innovation and cost control.

Adjusted earnings per share increased 9% at constant currency to 120.1p, while reported earnings reached 103.6p per share, up from 94.1p a year earlier.

The company continued its capital return strategy, completing £1bn in share buybacks in 2024 and announcing a £1.5bn buyback programme for 2025, with £150m already executed.

Relx also raised its full-year dividend by 7% to 63p per share, reflecting its strong financial position.

Portfolio development included five acquisitions for £195m, and seven disposals for £95m.

Net debt-to-EBITDA declined to 1.8x from 2.0x, with net debt standing at £6.56bn at the end of the year.

Relx said it was confident in its outlook, citing positive momentum across the business, expecting another year of strong underlying growth in revenue, profit, and earnings per share.

"Relx delivered strong revenue and profit growth in 2024," said chief executive officer Erik Engstrom.

"Our improving long-term growth trajectory continues to be driven by the ongoing shift in business mix towards higher growth analytics and decision tools that deliver enhanced value to our customers across market segments.

"We develop and deploy these tools across the company by leveraging deep customer understanding to combine leading content and data sets with powerful artificial intelligence and other technologies.

"This has been a key driver of the evolution of our business for well over a decade, and will remain a key driver of customer value and growth in our business for many years to come."

At 0818 GMT, shares in Relx were up 0.51% at 4,146p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.